AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
ARIA (Atacand Renoprotection In NephropAthy Pt.)
Phase 4
Completed
- Conditions
- Non-diabetic Nephropathy With Hypertension
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00573430
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00573222
- Locations
- 🇭🇷
Research Site, Zagreb, Croatia
🇭🇷Croatia, Zadar, Croatia
Open Label, Dose Escalation Phase I Study of AZD2281
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00572364
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Completed
- Conditions
- GERD
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT00567619
- Locations
- 🇦🇹
Research Site, Vienna, Austria
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 67130
- Registration Number
- NCT00567021
SYMBICORT® in the Treatment of COPD
Completed
- Conditions
- COPD
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00564499
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
Completed
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00562458
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00562250
- Locations
- 🇦🇷
Local Institution, Vicente Lopez, Buenos Aires, Argentina
Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia
Completed
- Conditions
- Patients With Dyslipidemia
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00557778
- Locations
- 🇧🇷
Research Site, Campinas, Sao Paulo, Brazil
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00557297
- Locations
- 🇱🇻
Research Site, Ventspils, Latvia
© Copyright 2025. All Rights Reserved by MedPath